Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...

Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) rose 7% following the company's announcement of its intent to submit a ...

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

Travere Therapeutics (TVTX) announced the Company has completed its Type C meeting with the U.S. Food and Drug Administration and plans to ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...

We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Travere Therapeutics, Inc.

We recently published a list of These 10 Companies Led Tuesday’s Charge. In this article, we are going to take a look at ...

Elizabeth E. Reed, Senior Vice President, General Counsel, and Corporate Secretary of Travere Therapeutics, Inc. (NASDAQ:TVTX), reported selling 8,000 shares of the company's common stock. The sale, ...

Travere Therapeutics aims to seek traditional approval based on data from the Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI, with submission expected by the end of the first quarter of 2025. The ...

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its target price hoisted by equities researchers at Canaccord Genuity Group from $22.00 to $45.00 in a research report issued on ...